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Abstract: In recent years, advances in pharmaceutical processing technologies have resulted in
development of medicines that provide therapeutic pharmacokinetic exposure for a period ranging
from weeks to months following a single parenteral administration. Benefits for adherence, dose
and patient satisfaction have been witnessed across a range of indications from contraception to
schizophrenia, with a range of long-acting medicines also in development for infectious diseases such
as HIV. Existing drugs that have successfully been formulated as long-acting injectable formulations
have long pharmacokinetic half-lives, low target plasma exposures, and low aqueous solubility.
Of the statins that are clinically used currently, atorvastatin, rosuvastatin, and pitavastatin may have
compatibility with this approach. The case for development of long-acting injectable statins is set
out within this manuscript for this important class of life-saving drugs. An overview of some of the
potential development and implementation challenges is also presented.
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Cardiovascular disease remains the leading cause of death in older adults, accounting for 60%
of deaths in those aged 85 years or older [1,2]. Hypercholesterolemia is a major risk factor for the
progression of atherosclerosis, the primary cause of coronary heart disease [3]. Statins are effective in
lowering blood cholesterol and are widely used in the pharmaceutical prevention of cardiovascular
disease [4]. It is estimated that with each 1.0 mmol/L reduction in blood low density lipoprotein
(LDL) cholesterol, there is a corresponding 22% reduction in the rate of major vascular events (defined
as coronary death, non-fatal myocardial infraction, coronary revascularisation or stroke) and a 14%
reduction in overall vascular mortality [5,6]. Statins are the most commonly prescribed lipid-modifying
therapies, with over 25 million people worldwide receiving therapy [7]. Additionally, the use of statins
in those aged 79 years and older has increased four-fold in proportion to the rise in prevalence of
cardiovascular disease for this population in the past decade [1,8].
Seven statins are currently approved for clinical use in at least one country [9] (Table 1). Despite
differences in their chemistry and pharmacokinetics, all statins lower blood cholesterol through the
competitive inhibition of the enzyme, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase,
which catalyses the conversion of HMG-CoA to mevalonate, the rate limiting step in cholesterol
synthesis. The competitive inhibition of HMG-CoA decreases hepatocyte cholesterol synthesis and
the reduced intracellular cholesterol concentration induces the expression of LDL receptors on the
hepatocyte cell surface. This results in increased extraction of LDL cholesterol from the blood and
effectively reduces circulating LDL cholesterol [4,10]. Statins have also been shown to have beneficial
effects on other lipid parameters including increasing high-density lipoprotein (HDL) cholesterol and
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decreasing triglyceride concentrations in the blood [11]. Additionally, lipoprotein abnormalities are
frequently observed in patients with metabolic syndrome or type 2 diabetes [12]. A significant number
of these patients remain at risk of cardiovascular disease despite achieving the recommended LDL
cholesterol concentration [13]. Fibrates are commonly co-administered in patients with high residual
risk and, like statins, are lipid profile modifying drugs [14]. Fibrates regulate the expression of genes
involved in multiple metabolic pathways leading to reductions in plasma triglyceride concentrations
and increasing HDL cholesterol levels [15]. Therapeutic interventions based on statin and fibrate
combinational therapy has been shown to be particularly effective in patients when a number of lipid
parameters need to be addressed and is not achievable with statin therapy alone [14].
Despite the clinical utility of statins, there are limitations associated with their current use.
Of particular relevance to the current manuscript, a recent systematic review highlighted that rates
of patient adherence to statins ranged between 17.8% and 79.2% [16], and a previous meta-analysis
showed that only 60% of 1,978,919 patients were adherent to statins being used for primary or secondary
treatment. Importantly, adherence is related to the efficacy of statins. Observational studies have
shown a relationship of adherence with cholesterol and cardiovascular disease, with patients having
adherence ≥90% seemingly more likely to have a ≥25% reduction in LDL than those in the 80–89%
adherence range [16–18]. Older age is well known to be associated with lower adherence to medication
generally, and retirement has been shown to specifically impact adherence to statins [19]. Accordingly,
the need for improved strategies and interventions to tackle non-adherence to statin therapy has been
recognised [20].
In recent years, long-acting drug delivery has emerged as an effective approach for management
(therapy and prevention) of indications requiring chronic drug administration, particularly where low
patient adherence to medication negatively impacts outcomes. Long-acting terminology is already
applied to statins to discriminate long half-life from short half-life drugs and so definition warrants
clarification. Accordingly, long-acting in the context of this manuscript is defined as the advanced
drug delivery approaches that provide therapeutic drug exposure for a period ranging from several
weeks to several months after a single dose. Several such approaches to long-acting delivery exist, each
presenting different development, financial, clinical, and logistical challenges and opportunities. Drug
delivery implants have proven highly successful for potent contraceptive agents that require low target
plasma concentrations. However, when higher plasma concentrations are needed, insufficient drug can
be loaded into tolerably sized implants, and multiple implants are frequently used to obtain sufficient
and sustained drug exposure even for highly potent contraceptives. Conversely, long-acting injectable
(LAI) medicines are widely applicable across indications providing drug exposure for a period between
two and 12 weeks from a single parenteral administration (intramuscular or subcutaneous). Licensed
LAIs are available for contraception [21], schizophrenia [22,23], opioid addiction [24], androgen
ablation [25], and hypogonadism [26]. LAI medicines are also in late stage development for the
treatment of HIV [27], with preclinical proof-of-concept emerging across infectious diseases [28–30].
As well as the obvious advantages of tackling issues of non-adherence, LAI medicines have proven
highly popular with patients with schizophrenia across many country contexts [31,32]. Early signs of
popularity are also evident for the long-acting HIV medicines in phase II trials and an appetite for the
approach from general patient groups [27,33]. Many patients become tired of taking oral pills on a
daily basis, which is also a constant reminder of their disease that is mitigated when moving from oral
to long-acting therapy.
Existing LAI rely upon oil depot formulations (e.g., fluphenazine, testosterone), polymer
microsphere encapsulation (e.g., naltrexone, risperidone), or aqueous particle suspensions
(e.g., paliperidone palmitate, olanzapine pamoate, leuprolide mesylate, aripiprazole lauroxil,
medroxyprogesterone acetate, rilpivirine, cabotegravir). Polymer microspheres require high polymer
to drug ratios to control drug release, resulting in low active drug ratio and restricting the achievable
duration when high doses are required. Oil depot formulations have needed new prodrugs to increase
lipophilicity and achieve high oil concentrations to provide adequate doses (e.g., haloperidol decanoate,
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fluphenazine decanoate, testosterone undecanoate). They must also be administered slowly and are
commonly associated with administration pain and skin reactions that can persist for up to three
months. Aqueous particle suspensions are more tolerable, some require prodrug derivitisation but
existing orally administered drugs are sometimes compatible directly, which reduces the regulatory
bar for rapid introduction. Importantly, despite the need for advanced processing technologies that
sometimes manipulate the drug at the nanometer scale, many of these approaches are highly cost
effective with emerging interest for applications even in low- and middle-income countries [34].
There is currently a paucity of knowledge relating to the mechanisms for drug absorption and what
makes the ideal LAI drug molecule [35]. However, existing LAI medicines have a long pharmacokinetic
half-life, low water solubility, and low target plasma concentrations. Oral half-life correlates with LAI
half-life but is extended through flip-flop kinetics. In a basic sense, a drug cannot be cleared until it is
absorbed so the rate of drug elimination approaches the rate of absorption. Water-soluble drugs cannot
be utlilised because of rapid dissolution and potential for dose-dumping. Low target concentrations
are a prerequisite for the approach because high plasma concentrations are harder to achieve and
sustain for long periods of time.
A review of the data for existing clinically used statins reveals that three exhibit physicochemical
and pharmacological properties that may make them compatible with formation of aqueous particle
suspensions for LAI delivery. The oral pharmacokinetic half-life, aqueous solubility, and plasma
concentration achieved after oral administration (surrogate for plasma target concentration) are
summarised in Table 1. Atorvastatin, rosuvastatin, and pitavastatin have low aqueous solubility, low
target plasma concentrations, and reasonably long half-lives, all broadly within the range of drugs that
have previously been successfully developed into LAI formulations.
When administered orally, absorption of statins is rapid but highly variable (Table 1) [36–39].
Most existing LAI medicines exhibit greater pharmacokinetic variability than their oral counterpart
medicines and careful monitoring may be needed for an LAI equivalent to establish effective and safe
exposures. Absorption is also affected by time-of-day administration and statins with short half-lives
of 3 h or less are best administered in the evening when the rate of cholesterol synthesis is highest [4].
Statins with longer half-lives such as atorvastatin can be administered any time of day and shows
greater efficacy for lowering LDL cholesterol compared to older statins, partly due to the longer
residence time of the drug [40]. Clearly, the need to consider time of day dosing would be obviated
for an LAI because administration would occur monthly or less frequently with a flattening of the
pharmacokinetic profile across the dosing interval.
Plasma protein binding is extensive for all the statins except pravastatin, resulting in low systemic
exposure to the unbound pharmacologically active drug (Table 1) [36]. Statins are amphiphilic and
enter hepatocytes either directly by membrane interactions in the case of lipophilic agents or via
carrier proteins in the case of hydrophilic agents [41]. Additionally, the uptake of statins is influenced
by the drug transporters OATP1B1 and/or ABCC2 in the liver [42]. Most statins undergo first-pass
liver metabolism, significantly reducing systemic bioavailability [43]. Atorvastatin, simvastatin and
lovastatin are primarily metabolised by CYP3A4 although other pathways play a minor role in metabolic
processing [11]. Active metabolites have been described for these drugs, inhibiting HMG-CoA reductase.
The main active metabolites for atorvastatin are 2-hydroxy- and 4-hydroxy-atorvastatin acid [44].
Fluvastatin is primarily metabolised by CYP2C9 although CYP3A4 and CYP2D6 may also play a
modest role [45]. Pravastatin, pitavastatin and rosuvastatin do not undergo substantial metabolism by
CYP isoenzymes [42]. The principal route of elimination for most of the statins is via biliary excretion
following metabolism by the liver. Pravastatin and rosuvastatin are eliminated mostly as unchanged
drug by both the liver and kidneys [4].
Simvastatin and lovastatin are administered orally as lactone prodrugs and are enzymatically
hydrolysed in vivo to their active hydroxy-acid form. The remaining statins are administered in
their active hydroxy-acid form [3,4]. It is estimated that equal amounts of the acid and lactone
forms of atorvastatin and simvastatin are present in human plasma whereas less than 5% of
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fluvastatin and pravastatin is present in the lactone form [46–48]. It has been suggested that
conversion from the acid to the lactone form is mediated by glucuronidation via uridine diphosphate
(UDP)-glucuronosyltransferase 1A1 (UGT1A1) and UGT1A3 and/or β-oxidation reactions in the
liver [49,50]. Lactonised statins can be metabolised via a number of pathways, including, directly
by CYP isoenzymes which occurs more rapidly than for the corresponding acid forms, or the
lactonised statin may be converted back to the acid form by hydrolysis via chemical interconversion
by estereases/paraoxenases and subsequently be metabolised [42,48,51]. Delivery of drugs through
formation of LAI medicines doesn’t alter the composition of the drug systemically, even with approaches
involving nanotechnology. Unlike other nanotechnology-based approaches to drug delivery, aqueous
particle dispersions are composed of only drugs with excipient that are already pharmaceutically
accepted and chosen from the Food and Drug Administration (FDA) Center for Drug Evaluation
and Research (CDER) list. Importantly therefore, the drug is in the same form within the systemic
circulation following absorption from oral or LAI delivery, meaning that the distribution, metabolism,
and elimination pathways remain unchanged. However, almost all LAI medicines require lower doses
than their oral counterparts when averaged across the dosing interval. For example, rilpivirine and
cabotegravir require 1400 mg and 1700 mg for 2 months of therapy when given orally, but 600 mg and
900 mg, respectively, exhibit comparable efficacy when given as LAI [27]. Similarly, reductions in dose
are evident across other LAI medicines [35].
Statins are safe and effective in the majority of patients [7]. However, they are associated with
muscle complaints including myalgia, cramps and weakness that can compromise quality of life and
reduce compliance to medication [52,53]. The incidence of patient reported myalgia during statin
therapy ranges from 1% in controlled studies to 25% in clinical reports [52,54]. The clinical spectrum of
statin induced myopathy (SIM) ranges from asymptomatic elevations in creatine kinase (CK) without
muscle pain to, in very rare incidences, potentially life-threatening rhabdomyolysis with high CK
and potential for acute kidney injury [7]. Therefore, if statins are to be developed into LAI medicines
then it will be critical to consider the implications for myopathy and use this to inform drug selection.
The mechanisms that underpin SIM are not fully understood, although more lipophilic statins such as
simvastatin and lovastatin appear more toxic [41,55]. A number of risk parameters have been reported
for developing SIM including patient factors, such as advanced age, low BMI, comorbidities, excessive
physical exercise, and personal or family history of SIM [7]. Additionally, the combination of statins
with drugs that are known inhibitors of CYP3A4, CYP2C9 or OATP1B1 potentially increases the risk of
SIM. In several studies, although not all, plasma concentrations of statin or statin metabolites were
higher in patients with associated myopathy [7,56]. If myopathy is concentration-dependent, then
there may be advantages to LAI-based delivery because high daily maximum plasma concentrations,
required to maintain overall exposure, are avoided by the approach.
Many LAI medicines require intramuscular administration in order to tolerably accommodate the
high doses required for long durations of exposure. For example, a 3 mL intramuscular injection every
eight weeks is being progressed for each of the LAI antiretrovirals cabotegravir and rilpivirine [27].
This may seem counterintuitive for drugs that exhibit muscle toxicities. However, a number of
studies have identified the involvement of metabolites in the development of SIM. Skottheim et al.,
incubated primary human myoblasts with increasing concentrations of lactone and acid forms of
different statins. Quantitative measurements of myotoxicity revealed that the lactone forms of all
the studied statins decreased the number of living myotubes compared to the respective acid forms.
Atorvastatin-, fluvastatin-, pravastatin- and simvastatin-lactone showed a 14-, 26-, 23- and 37-fold
increase in myotoxicity compared to the corresponding acid forms, respectively [48]. Hermann et
al., compared the pharmacokinetics of atorvastatin and its metabolites in healthy control patients
and patients with SIM. The patients with myopathy had a 2.4- and 3.1-fold increase in exposure in
atorvastatin-lactone and para-hydroxy-atorvastatin, respectively. However, no significant difference in
exposure to the pharmacologically active acid form was observed between the two groups. The authors
noted that increased exposure to atorvastatin-lactone was observed in patients with and without
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concomitant treatment with CYP3A4 inhibitors. Additionally, atorvastatin-lactone is significantly more
lipophilic than the acid form and expected to have a higher tissue penetration. Therefore, patients with
increased exposure to atorvastatin-lactone, either inherently or due to interacting drugs, could have
increased tissue exposure which may account for the increased risk for myopathy [57]. More recently,
it has been demonstrated that lactonisation of atorvastatin is mainly mediated by UGT1A3, with an
increased rate in carriers of the UGT1A3*2 haplotype. This suggests that lactonisation is at least partly
enzymatically controlled [58]. If the causative metabolite for SIM is generated predominantly within
the liver, then the route of administration may not influence the incidence of this toxicity. The avoidance
of oral first-pass metabolism by parenteral administration may also prove beneficial, but this would
need to be empirically assessed as part of any LAI statin development programme.
Table 1. Relevant pharmacokinetic, pharmacodynamic and physiochemical properties of statins.
Standard
Daily Dose
(mg)
Oral
Bioavailability
(%)
IC50
HMG-CoA
Reductase (nM)
Aqueous
Solubility
(mg/mL)
Plasma Target
Concentration
(ng/mL) *
Elimination
Half-Life
(h)
Pravastatin 10–40 [43] 18 [43] 4 [43] 0.006 [59] ~1.0 a [60] 1.8 [4]
Lovastatin 10–40 [43] 5 [43] 2–4 [43] 0.0004 [59] ~1.7 a [39] 3 [4]
Simvastatin 10–40 [43] <5 [43] 1–2 [43] 0.01 [59] 1.4 b [61] 2 [4]
Fluvastatin 80 [43] 30 [43] 3–10 [43] 0.0005 [59] 1.9 b [62] 1.2 [4]
Atorvastatin 10–80 [43] 12 [43] 1.16 [43] 0.000001 [59] 5.0 b [63] 14 [4]
Rosuvastatin 5–40 [43] 20 [43] 0.16 [43] 0.02 [59] 0.5 b [64] 19 [4]
Pitavastatin 1–4 [43] 60 [43] 0.1 [43] 4 × 10−4 [59] 2.5 b [65] 11 [4]
* Steady-state Ctrough at 12 h a or 24 h b post dose.
It is important to recognise that patients with hyperlipidemia undergoing therapy with statins
frequently also require treatment for comorbid conditions such as diabetes and cardiovascular disease.
This clearly has important implications if LAI statins are to be effectively developed and deployed.
Firstly, patients that are non-adherent to statin therapy are also more likely to also be non-adherent to
their co-medications. Clearly, availability of LAI statins will not mitigate the need for strict adherence
to the co-medications and alternative strategies may also be needed for these other agents. Secondly,
there is currently limited knowledge regarding whether the drug–drug interaction potential is altered
when drugs are formulated for LAI. It is possible that for some interactions, the avoidance of the
gastrointestinal tract and first-pass metabolism may decrease the likelihood or magnitude. However,
further work is clearly needed to understand the liability of LAIs as both perpetrators and victims of
drug interactions.
In summary, benefits for adherence, dose requirement and patient satisfaction have been achieved
across indications by the development of LAI medicines. Three existing statins may be compatible
with LAI development using advances in nanoparticle formulation technologies. Non-adherence to
statins has important consequences for therapy outcome that may be avoided by LAI deployment.
The approach may not necessarily exacerbate issues with toxicity of statins, and may be mitigated by
the requirement for lower doses, lower maximum plasma exposures and careful analysis relating to
route of administration. Benefits must be weighed against the potential for higher variability in drug
exposure after LAI administration. However, development of LAI statin medications seems worthy of
further consideration.
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